Nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau lapaʻau Trazhenta

Aia i kēlā me kēia papa pākuʻi ʻoniʻou: kaha mea: linagliptin 5 mg,

nā mea waiwai: mannitol, kōpio pregelatinized, copovidone, magnesium stearate, Opadray pink (02F34337) (hypromellose 2910, titanium dioxide (E171), talc, macrogol 6000, oxide iron oxide (E172)).

ʻO nā papa poli biconvex me nā kihi beveled, i uhi ʻia me ka pale kiʻi ʻoniʻoni ʻulaʻula māmā, me ke kahakaha ʻana o ka hōʻailona o ka hui ma kekahi ʻaoʻao a me ke kaha kiʻi "D5" ma kēlā ʻaoʻao o ka pā.

Ka hana lāʻau lapaʻau

ʻO Linagliptin ka mea lawe i ka peptidase o ka enzyme dipeptidyl-4 (ma aneʻifter - DPP-4), i pili ia i ka hana ʻole ʻana o nā hormone addetins - pona-like peptide-1 (GLP-1) a me ka glucose-e hilinaʻi i ka insulinotropic polypeptide (GIP). Hoʻopau koke ʻia kēia mau hormones e ka DPP-4 ene. Ua pili kēia mau lāʻau ʻelua i ka hoʻoponopono kino o ka physiological o ka home home home glucose. ʻO ka pae haʻahaʻa o ka neʻe o ka puke i ka lā i hoʻohaʻahaʻa ʻia, ke piʻi wikiwiki nei ma hope o ka ʻai. Hoʻonui ʻo GLP-1 a me GIP i ka biosynthesis insulin a me kāna mea huna e ka pancreatic beta-ketki ma ka pae kiʻekiʻe a hoʻoneʻe i ke kahe koko. Eia kekahi, hōʻemi ʻo GLP-1 i ka huna ʻana o ka glucagon e nā ʻāpana alpha pancreatic, e alakaʻi ai i kahi emi o ka hana glucose i loko o ka ate. ʻO Linagliptin (TRAGENT) kahi hana maikaʻi a hoʻololi hou i ka pilina me DPP-4, ka mea e hoʻomāhuahua mau i ka pae o ka wiki a me ka mālama lōʻihi i kā lākou hana. Hoʻonui ʻo TRAGENTA i ka huna ʻana i ka glucose o ka glucose a hoʻemi i ka ʻōlelo huna o ka glucoseagon, e hoʻopiʻi ana i ka holomua o ka home home home glucose. Hoʻopili ka Linagliptin iā DPP-4 maʻalahi, ma in vitro kona koho ʻana ma mua o ka selectivity no DPP-8 a i ʻole he hana no DPP-9 ma mua o 10,000 mau manawa.

Lapaʻau lāʻau

ʻO ka hoʻoneʻeʻana o ka linagliptin i ka plasma e hoʻoemi ana i ʻekolu-manawa. He lōʻihi ka hapalua o ka pahu noho, ʻoi aku ma mua o 100 mau hola, aia ka nui ma muli o ka paʻa mau ʻana o ka linagliptin me ka DPP-4 enzyme; ʻaʻole i kū ka hōʻuluʻulu lāʻau. ʻO ka hapalua ola maikaʻi, ma hope o ka hoʻokele mau ʻana o linagliptin i kahi dosis o 5 mg, aneane 12 mau hola. I ka loaʻa ʻana o ka linagliptin ma kahi o ka nui o 5 mg i hoʻokahi manawa i ka lā, ua hoʻokō ʻia ka paʻa ʻana o ka plasma i ka lāʻau ma hope o ke kolu o ka make. I ka wā o ka noho palaka o ka pharmacokinetics (ma hope o ka lawe ʻana i ka lāʻau lapaʻau ma kahi o ka nui o 5 mg), ʻo AUC (wahi ma lalo o ka cur-time kukui) o ka linagliptin plasma i hoʻonui ʻia ma kahi o 33% i hoʻohālikelike ʻia me ka uku mua.

ʻO nā mea liʻiliʻi o nā coefficient a me nā coefficient o ka ʻano ma waena o nā mea maʻi no ka AUC o linagliptin he liʻiliʻi (12.6% a me 28.5%, kekahi). ʻO nā kumu nui o ka plasma AUC o ka linagliptin me ka hoʻonui nui e hoʻonui i ka pākuʻi ʻana. ʻO nā pharmacokinetics o linagliptin i nā limahana olakino a me nā mea maʻi me ka maʻi diabetes mellitus type 2 ua like like.

ʻO ka bioavailability piha o linagliptin e pili ana i ka 30%. ʻO ka loaʻa ʻana o ka linagliptin me ka meaʻai e loaʻa ka nui o nā momona, hoʻonui i ka manawa o ka hoʻokō me_tah 2 mau hola a hōʻemi i C_tah 15%, akā ʻaʻohe hopena i A11Co-72ch- He hopena koʻikoʻi nui o nā loli C_tah a T_tah ʻaʻole i manaʻo ʻia. No laila, hiki ke hoʻohana pū ʻia ka linagliptin me ka meaʻai a me ka ʻole o ka hoʻokomo o ka meaʻai.

Ma muli o ke kau ʻana i nā lāʻau lapaʻau i nā ʻili, ʻo ka nui o ka ʻike ākea o ka hoʻoili ʻia i loko o kahi mākeke o ka pharmacokinetics ma hope o kahi lawelawe alaka i ka linagliptin i loko o kahi pākaʻi o 5 mg i nā kumuhana olakino he 1110 lita, e hōʻike ana i ka hoʻonui nui i nā kiko. ʻO ka paʻa ʻana o ka lignagliptin i nā protein o ka plasma e hilinaʻi ana i ka paʻa o ka lāʻau a ma kahi o 99% i ka neʻe o ka 1 nmol / L, a me nā hōʻemi o 30 30 nmol / L i ka emi ʻana i ka 75-89%, e hōʻike ana i ka saturation o ka paʻa o ka lāʻau me DPP-4 me ka hoʻonui nui ʻana o ka lignagliptin . ^ E Ha yM. I nā kikowaena kiʻekiʻe, ke kaomi piha ʻana o DPP-4, 70-80% o linagliptin e hoʻopaʻa ai i nā protein plasma (ma mua o DPP-4), a me 30-20% o ka lāʻau i loko o ka plasma i loko o kahi kūlana ʻole.

Ma hope o ka lawelawe waha ʻana i hoʻopaʻa ʻia i ka 14C-linagliptin ma kahi lāʻau o 10 mg me ka urine, ma kahi o 5% o ka radioactivity e hoʻokuʻu ʻia. Mālama ʻia kahi hapa o ka lāʻau lapaʻau. Ua loaʻa i ka metabolite koʻikoʻi, ka hana o kēlā me ka 13.3% o nā hopena o ka linagliptin i ke kahua o ka ʻoihana pharmacokinetics, ʻaʻole i loaʻa ka hana pharmacological a ʻaʻole i hoʻopilikia i ka hana pale o lignagliptin i ka plasma ma DPP-4.

4 mau lā ma hope o ka hoʻomalu ʻana o ka linagliptin hōʻailona 14C i loko o nā kumuhana olakino, ma kahi o ka 85% o ka nui e kāwā ʻia (me nā feces 80% a me ka urine 5%). ʻO ka hoʻomaʻamaʻa kaulela ma ka kālaila ʻoi aku ka lōʻihi ma kahi o 70 ml / min.

Hola paʻa kino hana

No ka loiloi i ka pharmacokinetics o linagliptin (ma kahi o ka nui o 5 mg) i nā mea maʻi me nā ʻano like ʻole o ka maʻi maʻamau i hoʻohālikelike ʻia me. nā kumuhana olakino i mālama i kahi noi hana wehe me ka nui regimen dosing. No ka noiʻi pū kekahi i nā mea maʻi me ka maikaʻi ʻole o ka renal, i hoʻokaʻawale ʻia ma muli o ka cleince clearance i ka pūpū (50 - 2.

ʻAʻole koi ʻia nā loli ma ke ʻano o ke ʻano o nā mea maʻi. ʻAʻole i loaʻa i ka hopena koʻikoʻi ka maʻi i ka pharmacokinetics o linagliptin (e like me nā hopena o kahi heluna ʻoakiko i hoʻākāka i hana ʻia ma ke kumu o nā ʻike mai nā haʻawina o ka manawa I a me ke ʻano II).

ʻAʻole pono ka hoʻoponopono ʻana o ka maʻi maʻi e like me ka makahiki o nā mea maʻi, no ka mea, ʻaʻole i loaʻa ka hopena koʻikoʻi o nā maʻi i ka pharmacokinetics o linagliptin. I nā poʻe maʻi maʻi (65-80 mau makahiki, ʻo ka mea maʻi ma mua loa. He 78 mau makahiki) a i nā mea maʻi o nā makahiki ʻōpio, ua hoʻohālikelike ʻia ka hui ʻana o ka linagliptin.

ʻAʻole i hana ʻia nā noi ʻana o nā pharmacokinetics o lignagliptin i nā keiki.

Nā hōʻailona no ka hoʻohana ʻana

Hōʻike ʻia ka TRAGENT no nā maʻi pākeke me ka maʻi diabetes mellitus type 2 i mea e hoʻomaikaʻi ai i ka mana glycemic: e like me ka monotherapy

- no nā mea maʻi me ka loaʻa ʻole o ka glycemic control wale nō ma o kaʻai a i ka hoʻomaʻamaʻa ʻana paha, a no ka poʻe hiki ʻole ke lawe i ka metformin ma muli o ka hoʻomalala ʻana, a i ʻole ka metformin e hui pū me ka hana pūpū.

- metformin, inā he meaʻai a me ka hoʻomaʻamaʻa ʻana me ka hui me ka metformin ʻaʻole i hāʻawi pono i ka mana glycemic kūpono,

- ka waiwai o ka sulfonylurea a me ka metformin, inā he meaʻai a me ka hana kino e hui pū ai me ia ʻano hui hoʻohui ʻole e hāʻawi i ka pono glycemic control,

- i ka like pū ka insulin me ka metformin a i ʻole, inā i ka ʻai a me ka hana kino e hui pū me ia ʻano hana, ʻaʻole e hāʻawi i ka mana glycemic kūpono.

ʻŌpū a me ka lactation

ʻAʻole i aʻo ʻia ka hoʻohana ʻana o linagliptin i nā wahine hāpai.

ʻAʻole hōʻike ʻia nā haʻawina holoholona i nā hōʻailona o ka hiki ke hoʻohālikelike. E like me ka mea nui o ka hana ʻana, pono e ʻalo ʻia ʻo TRIGENT i ka wā hāpai.

Hōʻike ʻia nā ʻike i loaʻa i nā noiʻi pharmacodynamic i nā holoholona i ka hoʻomaka ʻana o ka linagliptin a i kāna mau metabolites i loko o ka waiū umauma. Hōʻalo ka hopena o ka hōʻike ʻana i nā pēpē a keiki paha i ka wā ʻōpiopio.

ʻO ka hoʻoholo e pani i ka hōʻeha a lawe paha i ka TRAG pono e kau ʻia ma luna o nā pono o ka umauma pēpē no ka pēpē a me ka maʻi no ka makuahine.

ʻAʻole i hana ʻia nā haʻawina o ka hopena o TRAGENT i ka ulu kanaka. ʻAʻole hōʻike ʻia nā haʻawina holoholona i nā hopena maikaʻi ʻole e hūnā.

ʻLoe a me ke kākele

ʻO ka paona i ʻōlelo ʻia he 5 mg a lawe ʻia 1 ka manawa i kēlā me kēia lā.

Me ka hoʻohana ʻana me ka metformin, pono mau ka nui o ka metformin.

Ke lawe nei i ka linagliptin i hui pū me ka derivatives o sulfonylurea a i ʻole insulin, e noʻonoʻo pono nā haʻahaʻa o ka sulfonylurea a i ʻole derivatives e hana i nā mea e pono ai ka hypoglycemia.

Hola paʻa kino hana

ʻAʻole pono ka poʻe maʻi me ka maʻi ʻōnaehana renal functioning.

Hōʻeha ka hana ʻoluʻolu

Hōʻike nā hōʻike ʻo Pharmacokinetic e koi ʻole i ka hoʻoponopono ʻia ʻana o nā maʻi maʻi no nā mea maʻi me ka hana o ka puʻuwai maʻipaʻa, eia nō naʻe, ʻaʻohe ʻike me ka hoʻohana ʻana o ka lāʻau i ka lāʻau i kēlā mau mea maʻi.

ʻAʻole koi ʻia ka hoʻoponopono ʻana ma ke ʻano he makahiki.

Eia nō naʻe, pilikia ka ʻike loea ma nā mea maʻi ma mua o 80 mau makahiki, pono e mālama ʻia kēia pūʻulu o nā mea maʻi.

Na keiki a o ka opio

ʻAʻole paʻa i ka palekana a me ka hana o ka linagliptin no nā keiki a me nā ʻōpio.

Inā hala kahi dosis o ka lāʻau lapaʻau, pono e hoʻihoʻi i ka manawa e hoʻomanaʻo ka mea maʻi i kēia. Mai lawe i kahi pāpālua pālua i ka lā hoʻokahi.

Loaʻa ka hopena

ʻO ka palekana o TRAGENT i loiloi ma ka huina o nā 6602 mau maʻi me ka mellitus type type 2, e komo pū ana me nā 5955 nā mea maʻi e lawe ana i ka momona o 5 mg.

Hoʻokomo ʻia nā haʻawina e pili ana i ka placebo i nā haʻawina i hoʻohana ʻia ai ka linagliptin penei:

i ke ʻano o monotherapy (ka hoʻohana wā pōkole, hiki i nā 4 wiki)

like monotherapy (lōʻihi> 12 mau pule) hoʻohui i ka metformin

ʻO ka hoʻohui i ka metformin me ka sulfonylureas

hoʻohui me ka insulin e hui pū ai a i ʻole me metformin.

Ua hōʻike ʻia ke kaanū o nā hopena ʻaoʻao me: pinepine pinepine (> 1/10), pinepine (mai> 1/100 a 1/1000 a 1/10000 a

Ke keu

I ka wā o ka hoʻokolohua ʻana i nā maʻi lapaʻau i mālama ʻia i nā kumuhana olakino, hoʻokahi manuahi o ka linagliptin, e hōʻea ana i ka 600 mg (120 mau manawa i hoʻolilo ʻia). ʻAʻoleʻike kekahi kanaka me nā ʻōpoki ma mua o 600 mg.

Ma kahi o kahi overdose, pono e hoʻohana i nā hana maʻamau o kahi ʻano kākoʻo, no ka laʻana, ka hoʻopau ʻana i kahi lāʻau lapaʻau ʻole mai ka gastrointestinal tract, ka mālama kino ʻana a me ka mālama ʻana e like me nā hōʻike maʻi.

Hoʻopili pū me nā lāʻau ʻē aʻe

I ka hōʻike vitro hoʻonaninau lāʻau

ʻO Linagliptin kahi pale loulou ikaika o ka isoenzyme CYP3A4, a me kahi mea hōʻemi nawaliwali a hōʻemi pono paha i ka hoʻouka hana o kēia isoenzyme. ʻAʻole ʻo Linagliptin i kālai i nā likeenes CYP a ʻaʻole ia he inducer o lākou.

ʻO Linagliptin kahi papahele no ka helehelena P-glycoprotein (P-gp) a ke kāohi ʻia ma kahi liʻiliʻi P-glycoprotein-mediated transportasyon digoxin. Hāʻawi i kēia mau ʻikepili a me nā hopena o nā hōʻiliʻili o vivo, ʻo ka hiki ke linagliptin e launa pū me nā mea waiwai ʻē aʻe no ka P-gp i manaʻo ʻia.

Ma ka vivo lāʻau e hoʻoponopono nei i ka loiloi

ʻO ka hopena o nā lāʻauʻokoʻa'ē aʻe ma ka linagliptin

Hōʻike ka ʻike haʻawina ma lalo nei i kahi liʻiliʻi o nā hōʻiliʻili nui o nā maʻi me ka hoʻohana pū ʻana o nā lāʻau.

Metformin: ka hoʻohana pinepine ʻana o metformin i kahi manawa o 850 mg 3 mau manawa i ka lā a me linagliptin ma ke ʻano o ka 10 mg 1 manawa i kēlā me kēia lā ʻaʻole i alakaʻi i nā loli koʻikoʻi i loko o ka pharmacokinetics o linagliptin i nā mea hana olakino maikaʻi.

ʻO nā derivatives o Sulfonylurea: ʻaʻole i hoʻopilikia ʻia ka lāʻau lapaʻau ma ka moku o ka ʻoi ʻana o 5 mg o linagliptin e ka hui pū ʻana o ka waihona hoʻokahi ma ka 1.75 mg o glibenclamide (glyburide).

ʻO Ritonavir: ka hoʻohana pū ʻana o ka linagliptin (hoʻokahi pākahi o 5 mg maʻa) a me ka ritonavir (nui o nā inikua he 200 mg kūlohelohe), ka mea paʻa o ka P-glycoprotein a me ka isoenzyme CYP3A4, i hoʻonui i nā waiwai o AUC a me C_{t ka}ah linagliptin e pili ana i 2 mau manawa a me 3 mau manawa, kēlā. ʻO ka ʻaila manuahi, ʻo ia ka mea i emi o ka 1% o ka lāʻau lapaʻau o ka linagliptin, i hoʻonui i ka 4-5 manawa ma hope o ka launa ʻana me ka ritonavir. ʻO ka hoʻohālikelike ʻana o ka nānā ʻana o ka plasma o ka linagliptin i ka mokulāʻau i ka wahi o ka pharmacokinetics me a me ka ʻole o ritonavir i ka manawa like i hōʻike ʻia, he pono ka piʻi ʻana o ka ʻike i ka holo ʻana mai me ka hoʻonui ʻana o ka hōʻola lignagliptin ʻAʻole koʻikoʻi kēlā mau loli i ka lāʻau pharmacokinetics o lignagliptin. No laila, ʻaʻole i manaʻo ʻia nā hōʻiliʻili maʻi lapaʻau me nā mea ʻē aʻe P-glycoprotein / SURZA4.

Rifampicin: hoʻohana pinepine ʻia ʻana o 5 mg o linagliptin a me rifampicin, ka inducer ikaika o P-gp a me ka isoenzyme CYP3A4, i alakaʻi i ka hōʻemi o nā waiwai o AUC a me C_tah lignagliptin e 39.6% a me 43,8%, pākahi, a ma kahi o ka hoʻemi ʻana i ka hana o ka hana basal dipeptidyl peptidase-4 e pili ana i ka 30%. No laila, ʻaʻole i hoʻokō ʻia ka holomua o ka lapaʻau o ka linagliptin, i hui pū ʻia me P-gp active inducers, i ʻole me ka hoʻokō mau ʻia ʻana o ka hoʻohana ʻana. ʻO ka hoʻohana pū ʻana me nā mea hoʻoola ʻē aʻe o P-gp a me CYP3A4, e like me ka caramazepine, phenobarbital a me ka phenytoin, ʻaʻole i aʻo ʻia i ka palapala.

ʻO ka hopena o ka linagliptin i nā lāʻauʻokoʻa'ē aʻe

Ma nā haʻawina hōʻike maʻi, e like me ka hōʻike ʻana ma lalo nei, ʻaʻohe hopena koʻikoʻi o ka maʻi i ka pharmacokinetics o ka metformin, glyburide, simvastatin, warfarin, digoxin a me nā kūmole waha, i hōʻoia ʻia i vivo, a kau ʻia ma ka haʻahaʻa haʻahaʻa o ka linagliptin e komo i loko o ka pili o ka lāʻau me nā substrates no CYP3A4 , CYP2C9, CYP2C8, P-dr a me nā wahi i lawe i nā nūpepa ololi.

Metformin: ʻo ka hoʻohana pinepine ʻana o ka linagliptin ma kahi maʻa o 10 mg hoʻokahi i ka lā a me 850 mg o ka metformin, kahi māpala o nā kolo kūlohelohe, ʻaʻole i alakaʻi i ka pharmacokinetics nui o ka metformin i nā poʻe hanaola olakino. No laila, ʻo ka linagliptin, ʻaʻole ia he mea e pale aku ai iā Uransportag • hoʻopili ʻia e nā kolo kino.

ʻO nā derivatives o Sulfonylurea: ka hui pū ʻana o ka 5 mg o linagliptin a me hoʻokahi ka hopena o 1.75 mg o ka glibenclamide (gliburide) i alakaʻi i kahi hoʻoliʻikua kūmua i AUC a me C_tah glibenclamide e 14%. No ka mea ka nui o ka glibenclamide e ka CYP2C9, ua hōʻoia kēia mau ʻike ʻaʻole ʻo linagliptin i mea huna ma CYP2C9. ʻAʻole i manaʻo ʻia nā kikowaena koʻikoʻi me nā derony e pili ʻia ana me ka olony (e.g., glipizide, tolbutamide a me ka glimepiride), ka mea, e like me ka glibenclamide, ka mea nui i ka metabolly me CYP2C9.

ʻO Digoxin: hoʻohui i ka hoʻohana pinepine ʻana o 5 mg o linagliptin a me 0.25 mg o ka digoxin ʻaʻole i hoʻopilikia i ka pharmacokinetics o digoxin i nā limahana olakino. No laila, i ka vivo linagliptin, ʻaʻole ia he mea pale o P-glycoprotein-mediated.

Warfarin: linagliptin, hoʻopili pinepine ʻia i ka waihona o 5 mg i kēlā me kēia lā, ʻaʻole i loli i ka pharmacokinetics o S ​​(-) a i R (+) warfarin, he meaʻeha no CYP2C9 a lawelawe ʻia i hoʻokahi manawa.

Simvastatin: linagliptin i ka wā i lawe ʻia ai e nā mea kōkua olakino ma nā helu he nui liʻiliʻi kona hopena ma ka pharmacokinetics o simvastatin, kahi papa hoʻoluʻu no CYP3A4. Ma hope o ka lawe ʻana i ka linagliptin ma ke ʻano o 10 mg (ma luna o ke ʻano therapeutic) hui pū me simvastatin ma kahi o 40 mg no 6 mau lā, ʻo AUC o simvastatin i loko o ke kō koko a hoʻonui e 34%, a me C_tah i loko o ke koko koko - e 10%.

ʻO nā mea hoʻohālikelike waha ʻole: ʻo ka hoʻohana pū ʻana o linagliptin i kahi pāʻālua o 5 mg me ka levonorgestrel a ethinyl estradiol ʻaʻole i loli i ka pharmacokinetics o kēia mau lāʻau.

ʻO nā mea mālama palekana

ʻAʻole pono ke hoʻohana ʻia ʻo TRAGENT i nā maʻi me nā maʻi mellitus type 1 a i ʻole no ka mālama ʻana i ka ketoacidosis maʻi.

ʻO ka ulu ʻana o ka hypoglycemia i ka hihia o ka hoʻohana a linagliptin e like me ka monotherapy i hoʻohālikelike ʻia i ka placebo.

I nā haʻawina loiloi, hōʻike ʻia no ka like o ka hōʻeha o ka hypoglycemia i ka hihia o ka hoʻohana ʻana o linagliptin i hui pū me nā lāʻau lapaʻau ʻaʻole i manaʻoʻiʻo ke kumu hypoglycemia (metformin, thiazolidinedione derivatives) i like me nā hopena pletebo like.

Ke lawe nei i ka linagliptin i hoʻohui ʻia i ka derivatives sulfonylurea (me ka hoʻohui metformin therapy), hoʻonui ʻia ka nui o nā hihia o ka hypoglycemia like me ka hui plasebo.

Hiki i nā derivatives o nā sulfonylureas a me ka insulin e hana i ka hypoglycemia. ʻO Linagliptin e hui pū me ka derivatives sulfonylurea a / a i ʻole insulin e lawe me ka akahele. Inā makemake, he hōʻemi ʻawaʻawa o ka sulfonylurea a i ʻole derivatives e hana ʻia.

I ka wā o ka hoʻohana ʻana ma hope o ka hoʻohana ʻana i ka linagliptin, ua loaʻa i nā hōʻike pili i ka hoʻomohala ʻana o ka maʻi pancreatitis. Pono e hoʻomaopopo ʻia nā mea maʻi e pili ana i kahi hōʻailona o ka maʻi pancreatitis maha: ʻoi loa ka hōʻeha o ka ʻeha puʻuwai. ʻO ka hoʻoponopono ʻana o ka pancreatitis i nānā ʻia ma hope o ka hoʻokuʻu ʻana o ka linagliptin. Inā kānalua ka pancreatitis, pono e hoʻokuʻu ʻia ʻo TRAG.

E hoʻokuʻu i ke ʻano a me ka ʻano

Loaʻa ka trazenta i ke ʻano o nā papa kiʻi ʻoniʻoni: biconvex, i puni, me nā kihi beveled, ʻulaʻula kukui i ka ʻula, me kahi kiʻi kālai ʻia ʻo D5 ma kekahi ʻaoʻao a me ka hōʻailona o ka ʻoihana hana hana ma kēlā me kēia (7 pcs. In blisters, in a cardboard pack 2. 4 a i ʻole he 8 blisters, 10 pcs. I nā poli, ma kahi kāwele kāleka 3 mau palaka).

Kāleka i kēlā me kēia 1 papa:

• mea waiwai: linagliptin - 5 mg,
• nā mea kōkua: nā kuʻikahi pregelatinized, copovidone, ka mōʻī palaoa, ka mana o ka magnesium, mannitol,
• sheath film: Opadray ulaula 02F34337 (titanium dioxide, macrogol 6000, talc, hypromellose, dye iron oxide red).

ʻLoe a me ke kākele

Lawe ʻia nā papa ʻōlima. ʻO ka lawe ʻana i ka lāʻau lapaʻau ʻaʻole hilinaʻi ʻia i ka manawa o ka ʻai a hiki ke hana ma kēlā me kēia manawa o ka lā.

ʻO ka papa ʻōlelo ʻia e 1 papa (5 mg) hoʻokahi i ka lā.

Inā pau ka make maʻa, pono e lawe ka mea maʻi i ka lāʻau i ka manawa e hoʻomanaʻo ai i ka papa nalo. Hoʻopau i ka pāʻai a lawe i nā papa ʻelua i hoʻokahi lā ʻaʻole pono.

I ka hihia o ka pūnāwai kīnā ʻole a me / a o ka hana ʻana o ka lolo, a i nā mea maʻi ʻelemakule, ʻaʻole pono ka hoʻoponopono ʻana.

Nā hopena hopena

Hiki i nā hopena ʻaoʻao ke maʻamau i ka monotherapy me Trazent a me ka hui pū ʻana me nā ʻaina hypoglycemic ʻē aʻe:

• hoʻoweliweli nenoai: pancreatitis,
• ea kalepa
• ʻōnaehana pale: ka hopena o ka hypersensitivity,
• maʻi maʻi lēpa: nasopharyngitis.

ʻO nā lāʻau lapaʻau aʻe ma ke ʻano he hopena paʻakikī e hiki ke hōʻeha i nā hopena ʻaoʻao hou aʻe:

• pioglitazone, metformin a me pioglitazone: hyperlipidemia a me ka uku paona,
• kumuliiia:
• insulin: constipation,
• sulfonylurea derivatives a me metformin: hypoglycemia.

I ka manawa o ka nānā aku ʻana ma hope o ka kūʻai ʻana, ua ʻike ʻia nā hopena mai nā ʻaoʻao a me nā ʻatikala:

• digestive system: ulceration o ka mucous membrane o ka waha waha,
• ka hiʻona: urticaria, edema Quincke,
• ʻili: ʻili.

Nā ʻōlelo kikoʻī

Ke hoʻohana nei i ka lāʻau lapaʻau Trazhenta i ka manawa like me nā derivatives sulfonylurea, pono e hoʻomaʻamaʻa, no ka mea hiki i ka hopena ke kumu i ka hypoglycemia. Inā pono, hiki ke hoʻemi i ka nui o nā derivatives o ka sulfonylurea.

ʻAʻole hoʻonui ʻo Trazhenta i ka hopena o ka hoʻomohala ʻana i nā maʻi o ka ʻōnaehana cardiovascular.

Inā kānalua ka papa pancreatitis, pono e hoʻokuʻu ʻia ka lāʻau lapaʻau.

ʻAʻole i mālama ʻia nā ʻike loea e pili ana i ka hopena o ka linagliptin. ʻOiai ʻo kēia, ma muli o ka piʻi nui o ka dizzness, i ka wā e mālama ai me ka lāʻau lapaʻau, pono e hoʻomaʻemaʻe i ka mālama ʻana i ka wā e hana ai i nā hana e pono ai ka piʻi ʻana o ka nānā a me ka wikiwiki o ka hopena psychomotor.

Hoʻohui nūhou

Me ka hana like o ka lāʻau Trazent me ka metformin, glibenclamide, simvastatin, pioglitazone, warfarin, digoxin, rifampicin, ritonavir a me nā mea hoʻohālikelike waha, ʻaʻole i loli i ka pharmacokinetics o lignagliptin a me nā lālani i hoʻopili ʻia, ʻaʻole paha i loli nui.

Nā ʻano hana o ke noi Trazenti a me nā helu

Lawe ʻia ʻo Trazhenta i ka ʻōlelo maʻamau i loko o ka ʻōlelo i hoʻāno ʻia o 5 mg (1 papa) i hoʻokahi lā i ka lā.

Lawe ʻia ka hāmeʻa i kēlā me kēia manawa o ka lā, me ka ʻole o ka ʻai, ʻoi aku ka maikaʻi i kēlā me kēia lā i ka manawa like. Inā nele kekahi o nā papa, hiki iā ʻoe ke lawe i kēlā me kēia manawa i ka manawa e hoʻomanaʻo ana ka mea maʻi i kēia mea, akā nō naʻe, ʻaʻole ia ke noi ʻia e loaʻa i ka pālua ʻelua i hoʻokahi lā.

Hoike hōkeo

ʻO nā hua lāʻau he derivatives o ka sulfonylureas, i ka hapa nui, i hāpai i ka hoʻomohala ʻana o ka hypoglycemia. No laila, i kekahi mau hihia, hiki ke hoʻemi i kā lākou make ma ke koho ʻana me Trazhenta.

No nā mea maʻi me ka maikaʻi ʻole o ka renal, ua pono kēia lāʻau lapaʻau e lawe pū me nā lāʻau lapaʻau hypoglycemic ʻē aʻe.

Wahi a nā loiloi, ʻo Trazhenta a me nā analogues e hoʻemi nui ana i ka kao o ka hemoglobin glycosylated a me ka glucose e lawe i nā papa ʻaina.

Ma muli o ka hiki ʻole o ka dizziness, ʻōlelo ʻia ka mālama ʻana i ka wā e hoʻokele ana i nā kaʻa kaʻa a me nā mīkini kaumaha i ka wā o ka lāʻau lapaʻau.

Hōʻike nā ʻōlelo no Trazent e pono e mālama i nā papa i loko o kahi eleele, maloʻo, ʻoluʻolu a me ka hiki o nā keiki.